クイックアンサー — フォリスタチン344とは?
Follistatin 344 (FST-344) is a 344-amino-acid recombinant glycoprotein and the longer of the two principal splice isoforms of human follistatin. It is the canonical endogenous antagonist of myostatin (GDF-8) and activin, used in published studies investigating muscle hypertrophy, sarcopenia, muscular dystrophy preclinical models, and the activin/myostatin signalling axis. Supplied in 1 mg lyophilized vials.
📦 すべてのご注文は、当店の 再発送保証ポリシー — 万が一、20営業日以内に商品が届かない場合は、再発送いたします。
| 仕様 | 詳細 |
|---|---|
| CAS番号 | 80449-31-6(フォリスタチン) |
| タイプ | 組換え糖タンパク質(ヒトフォリスタチンの344アミノ酸スプライスアイソフォームFST-344) |
| 分子量 | 約37 kDa(成熟型糖鎖付加体;糖鎖付加状態に応じてSDS-PAGEで観察される範囲は約38~42 kDa) |
| 構造 | N末端ヘパリン結合ドメインに続いて3つのフォリスタチンドメイン(FSD1、FSD2、FSD3)が存在し、それぞれEGF様サブドメインとカザール様サブドメインを含む;システインリッチで、多数の分子内ジスルフィド結合を有する。 |
| 形態 | 凍結乾燥組換えタンパク質(白色~微黄色) |
| 純度 | ≥95%(HPLC検証済み、分析証明書はご要望に応じて) |
| 保管方法 | 凍結乾燥品:作業用ストックは2~8°C(冷蔵庫)、未開封バイアルの長期保管は−20°Cです。再溶解後:2~8°Cで約30日以内にご使用ください。光から保護してください。再溶解液の凍結融解は避けてください — 組換えタンパク質は特に凍結融解による変性を受けやすいためです。 |
| 溶解性 | 静菌水(推奨)または短い使用期間の場合は滅菌水をお使いください。作業希釈液の吸着ロスを最小限に抑えるため、キャリアタンパク質(BSA、0.1%)の任意添加をお勧めします。 |
フォリスタチン344とは何ですか?
Follistatin 344 (often abbreviated FST-344) is a recombinant 344-amino-acid glycoprotein and the longer of the two principal physiological splice isoforms of human follistatin — the other being FST-288, a shorter 288-amino-acid membrane-bound form. Endogenous follistatin was first isolated in 1987 from porcine ovarian follicular fluid by Esch et al. (PNAS) and Robertson et al. (Biochem Biophys Res Commun) as a factor that selectively inhibits follicle-stimulating hormone (FSH) secretion, which gave the protein its name. The mechanistic role — high-affinity binding and neutralisation of activin and myostatin — was characterised over the subsequent decade. FST-344 is a circulating, secreted isoform with a heparin-binding N-terminal domain followed by three cysteine-rich follistatin domains (FSD1, FSD2, FSD3) that together form the activin- and myostatin-binding surface. The recombinant 344-residue chain has a mature mass of approximately 37 kDa, with apparent molecular weight on SDS-PAGE varying between 38 and 42 kDa depending on the glycosylation state of the recombinant expression system. CAS number 80449-31-6. The protein is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. Follistatin is 承認されていません by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. For related anabolic and growth-axis studies, see our IGF-1 LR3 製品ページをご覧ください。
作用機序 — ミオスタチン・アクチビン経路拮抗作用
What makes follistatin 344 mechanistically unique among muscle-studies proteins is its 多標的結合プロファイル across the TGF-β superfamily — each ligand-binding event contributing to the observed hypertrophic and growth-modulatory phenotype in published studies:
- Myostatin(GDF-8)の隔離 — 筋肥大軸 — Follistatin binds myostatin (also called GDF-8) with high affinity, sterically blocking its interaction with the activin type II receptor (ActRIIB). Myostatin is the canonical endogenous negative regulator of muscle growth: knockout mice develop dramatic muscle hypertrophy (the “double-muscling” phenotype), and naturally myostatin-deficient cattle breeds (Belgian Blue, Piedmontese) show the same effect. By neutralising myostatin, follistatin removes the brake on muscle protein synthesis, producing hypertrophy in study models. This is the most-cited mechanism in the muscle-literature.
- Activin AおよびBの隔離 — 生殖、卵巣、下垂体シグナル伝達 — Follistatin’s original characterised function was binding and neutralising activin, a related TGF-β superfamily member that stimulates FSH secretion from the pituitary, drives ovarian follicle development, and acts as a regulator of many cell types. By binding activin A, B, and AB heterodimers, follistatin shifts the activin/inhibin balance in study models and modulates downstream Smad2/Smad3 signalling.
- GDF-11およびより広範なTGF-βスーパーファミリーの調節 — Follistatin also binds GDF-11 (closely related to myostatin) with somewhat lower affinity, alongside other TGF-β superfamily members. GDF-11 is increasingly studied in aging studies because its endogenous levels decline with age and its modulation is implicated in age-related cardiac and CNS phenotypes. Follistatin 344 is one of the principal tools for investigating this axis.
The three follistatin domains (FSD1, FSD2, FSD3) each contribute to the binding profile: FSD1 contains the principal myostatin-binding surface, FSD2 the principal activin-binding surface, and FSD3 contributes both binding affinity and structural stability. The heparin-binding N-terminal domain distinguishes the splice variants — FST-288 binds heparan sulfate strongly and is largely membrane-anchored, while FST-344 (this isoform) circulates more freely. This distinction is mechanistically relevant in study models studying systemic vs local follistatin effects.
Published Evidence
Follistatin 344 is used in clinical contexts that investigate:
- Muscle hypertrophy and protein synthesis studies — AAV-フォリスタチン遺伝子導入研究を含むマウスおよびラットの筋肥大モデル(Kota et al., Sci Transl Med 2009);筋線維タイプ別横断面積、筋湿重量、力発揮に関する研究
- 筋ジストロフィーの前臨床モデル — デュシェンヌ型筋ジストロフィーのmdxマウスモデル;機能的能力、筋線維再生、ジストロフィン非依存的な筋保存
- サルコペニアおよび加齢に伴う筋喪失 — aged-mouse muscle phenotypes, anabolic resistance, fibre-type-shift studies
- Cancer cachexia studies — 担癌マウスにおける悪液質モデル、体組成の保持、除脂肪体重/体脂肪量比
- Reproductive endocrinology studies — FSH suppression, ovarian follicle development, granulosa-cell biology, pituitary-gonadal-axis studies
- Activin pathway studies — Smad2/Smad3 signalling, EMT in cancer models, fibrosis studies, hepatic regeneration
- Aging and GDF-11 axis studies — cardiac and CNS aging phenotypes, parabiosis-related studies, GDF-11/myostatin balance with aging
- Comparative anabolic studies — ~との直接比較 IGF-1 LR3 (parallel anabolic pathway via IGF-1 receptor) for combined or comparative hypertrophy studies.
For broader context on where follistatin 344 fits within the anabolic and growth-axis studies landscape, see IGF-1 LR3 標準的なIGF軸比較対象として、, CJC-1295 with DAC for GHRH-axis growth studies, and Sermorelin for shorter-acting GHRH use. Browse the full ペプチドカタログ 化合物選択のために。
利用可能な力価と濃度
MedsBase stocks Follistatin 344 in 1 mg lyophilized vials. The vial is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:
| バイアル力価 | 代表的な使用例 | パックサイズ |
|---|---|---|
| 1 mg | Standard strength — muscle hypertrophy and activin/myostatin axis studies | 10、20、または30バイアル |
Follistatin 344 is a 37 kDa recombinant glycoprotein supplied at ≥95% HPLC purity. The 1 mg vial format is the standard strength for in vivo and in vitro work — one vial reconstituted with 1.0 mL bacteriostatic water yields a 1 mg/mL working concentration sufficient for many weeks of cell-culture protocols or several rodent-protocol injections.
Follistatin 344とIGF-1 LR3の比較
Follistatin 344と IGF-1 LR3 are the two most-cited recombinant anabolic proteins in current hypertrophy studies. They act on entirely different pathways — follistatin by removing the myostatin brake on muscle growth, IGF-1 LR3 by directly stimulating the IGF-1 receptor and downstream Akt/mTOR protein synthesis — which makes them mechanistically complementary in protocols.
| 評価項目 | Follistatin 344 | IGF-1 LR3 |
|---|---|---|
| アミノ酸数 | 344アミノ酸(組換え糖タンパク質) | 83アミノ酸(改変型IGF-1) |
| 分子量 | ~37 kDa | ~9 kDa |
| 主な作用機序 | ミオスタチン/アクチビン隔離 | IGF-1受容体作動 → Akt/mTOR |
| 効果モード | 脱抑制(成長ブレーキの解除) | 直接的な同化刺激 |
| 一般的な用量 | 10~100mcg、週1~3回 | 20~60mcg、毎日 |
| Strongest signal | 全筋肥大、ジストロフィーモデル | Local hypertrophy, regenerative anabolic studies |
| スタッキング | Commonly co-administered with IGF-1 LR3 in hypertrophy studies | フォリスタチン344との併用が一般的 |
Because the two proteins act on fundamentally different anabolic axes — follistatin removes the myostatin brake while IGF-1 LR3 directly stimulates protein synthesis — combined administration is commonly used in study models exploring maximal hypertrophic response. For studies interested in the myostatin pathway specifically, follistatin 344 is the canonical first choice; for IGF/Akt/mTOR anabolic studies, IGF-1 LR3 is the canonical tool.
保管方法と再溶解
再溶解前: 凍結乾燥バイアルは、短期使用の作業用ストックとして、元の包装のまま2~8°Cで冷蔵保存してください。未開封の長期保存の場合は、-20°Cで凍結してください。凍結乾燥フォリスタチン344は、冷蔵で最大12ヶ月間、-20°Cで最大24ヶ月間安定ですが、大型の組換え糖タンパク質は時間の経過とともに脱アミド化や酸化を受けやすいため、小型合成ペプチドよりも期間はやや短くなります。凍結乾燥粉末の凍結融解サイクルは避けてください。 再溶解手順: 静菌水をペプチドバイアルの側壁に沿って注入します(凍結乾燥ケーキに直接かけないでください)。1 mgバイアルの場合、1.0 mLの静菌水で1 mg/mLの作業濃度になります。静かに旋回させます—— しません 振盪し——5~10分間置いて完全に溶解させます。組換えタンパク質は小型ペプチドよりもゆっくりと溶解するため、溶解工程を急がないでください。適切に再構成された溶液は、透明で無色、目に見える粒子がないはずです。100 mcg/mL未満の作業希釈液では、キャリアタンパク質(BSAを最終濃度0.1%で添加)を加えることで、プラスチックやガラスへの吸着ロスを最小限に抑えます。 完全に再溶解した溶液は、無色透明である必要があります。 2~8°Cで冷蔵保存し、最適な安定性を得るために30日以内に使用してください。再構成した溶液を凍結しないでください——組換え糖タンパク質は特に凍結融解変性に敏感で、凝集や活性低下を引き起こします。濁り、沈殿物、変色が見られるバイアルは廃棄してください。
よくある質問
What is Follistatin 344 used for in studies?
Follistatin 344 is used in studies investigating muscle hypertrophy, muscular dystrophy preclinical models, sarcopenia, cancer cachexia, the activin/myostatin/GDF-11 signalling axis, reproductive endocrinology (FSH suppression, ovarian follicle development), and aging-related phenotypes. It is the canonical tool for myostatin pathway antagonism. The pharmaceutical-grade follistatin 344 sold here is しません FDA-approved and is supplied strictly for clinical studies use only.
フォリスタチン344とフォリスタチン315の違いは何ですか?
FST-344はシグナルペプチドを含む遺伝子産物の344アミノ酸アイソフォームであり、FST-315は分泌時のシグナルペプチド切断後の同じタンパク質です(したがってFST-315はFST-344の成熟循環型です)。両方の命名法は文献に登場し、同じ生物学的アイソフォームを指します。いずれも、より短い選択的スプライシングアイソフォームで、ヘパラン硫酸結合が強く主に膜結合局在を示すFST-288とは大きく異なります。
フォリスタチン344はIGF-1 LR3とどのように異なりますか?
Both are recombinant anabolic proteins used in muscle hypertrophy studies, but they target different pathways. Follistatin 344 is a 344-amino-acid glycoprotein that binds and sequesters myostatin and activin — it works by removing the endogenous brake on muscle growth. IGF-1 LR3 is an 83-amino-acid modified IGF-1 analog that directly agonises the IGF-1 receptor and activates Akt/mTOR protein synthesis. The two are mechanistically complementary and frequently co-administered in studies.
What is the typical Follistatin 344 dose?
Published preclinical protocols typically use 10–100 mcg per administration in rodent models, given 1–3 times weekly for 4–12 week cycles. Gene-delivery studies using AAV-follistatin produces tissue-localised concentrations that are difficult to compare directly to systemic-protein dosing. A 1 mg vial reconstituted with 1.0 mL bacteriostatic water yields 1 mg/mL — 0.01 mL equals 10 mcg, 0.1 mL equals 100 mcg.
Follistatin 344はFDA承認されていますか?
No. Follistatin 344 is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. AAV-follistatin gene therapy has been investigated in clinical trials for muscular dystrophy (e.g., Becker muscular dystrophy, inclusion body myositis) but is not FDA-approved.
Follistatin 344はどのように保管すればよいですか?
凍結乾燥品バイアル:短期使用の作業用ストックは2~8°Cで冷蔵保存、未開封バイアルの長期保存は-20°Cで冷凍保存してください。溶解液:2~8°Cで冷蔵保存し、30日以内にご使用ください。溶解液は凍結しないでください。組換え糖タンパク質は特に凍結融解による変性の影響を受けやすくなっています。常に直射日光を避けて保管してください。100mcg/mL未満の希釈液を作成する場合は、キャリアタンパク質(0.1% BSA)の添加を推奨します。
Follistatin 344の溶解方法を教えてください。
上記の溶解手順に従ってください。静菌水をバイアルの側壁に沿って加え(凍結乾燥ケーキに直接かけないでください)、静かに旋回させ、完全に溶解するまで5~10分間待ちます。激しく振ら しません ないでください。激しい攪拌は組換えタンパク質を変性させ、凝集を引き起こす可能性があります。正しく溶解された溶液は、無色透明です。1mgバイアルに1.0mLの溶解液を加えた場合、使用濃度は1mg/mLとなります。
純度の規格が99%ではなく95%なのはなぜですか?
Recombinant glycoproteins like follistatin 344 cannot achieve the ≥99% HPLC purity standard typical of small synthetic peptides because of the inherent heterogeneity of glycosylation in any recombinant expression system — different glycoforms appear as related peaks on HPLC that are not impurities but isoforms of the target protein. ≥95% HPLC purity is the standard pharmaceutical-grade specification for follistatin 344 and similar recombinant glycoproteins. SDS-PAGE typically shows a single band with the expected 38–42 kDa apparent mass range.
MedsBaseではどの容量のレタルトルチドを取り揃えていますか?
MedsBase carries Follistatin 344 in 1 mg lyophilized vials. The vial is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at ≥95% HPLC purity with a certificate of analysis available on request.
Can Follistatin 344 and IGF-1 LR3 be stacked in studies?
Yes. Follistatin 344 and IGF-1 LR3 act on fundamentally different anabolic axes (myostatin antagonism vs IGF-1 receptor agonism) and are frequently co-administered in study models exploring maximal hypertrophic response. The two are mechanistically complementary rather than redundant, and combined-protocol literature describes additive or synergistic effects on muscle fibre cross-sectional area.
Does Follistatin 344 cause side reported effects?
Published preclinical studies has documented tolerability at typical doses, with the main on-target effect being muscle hypertrophy. Off-target findings include modulation of FSH and ovarian function (because activin signalling is suppressed) and potential effects on hepatic regeneration and pituitary regulation due to follistatin’s role in broader TGF-β superfamily signalling. Systemic follistatin-protein dosing has different exposure characteristics than tissue-localised AAV-gene-delivery approaches.
Follistatin 344(フォリスタチン344)の半減期はどのくらいですか?
In preclinical studies, recombinant follistatin 344 has a plasma half-life of approximately 1–3 hours following intravenous administration, reflecting its size (37 kDa, above the renal filtration cutoff) and binding to circulating ligands. Tissue half-life is considerably longer because follistatin remains bound to its captured myostatin and activin targets, sequestering them away from receptors. Gene-delivery approaches produce a far longer effective duration of action because tissue expression continues over weeks to months.
How long does Follistatin 344 take to show effects in preclinical studies?
マウスおよびラットのタンパク質注射プロトコルにおける筋肥大効果は、通常、週1回投与で2~4週間後に統計的に有意となり、8~12週間を通じて蓄積し続けます。アクチビン/FSH軸への生殖エンドポイントへの影響は、投与後数日以内に検出可能です。遺伝子導入(AAV-フォリスタチン)プロトコルでは、注射後4~6週間までに測定可能な筋肥大が認められ、数ヶ月にわたって進行し続けます。
Follistatin 344を国際配送で注文できますか?
Yes. MedsBase ships Follistatin 344 worldwide from our dedicated peptide shipping network. Peptide-only orders qualify for our standalone peptide shipping service. All orders ship in temperature-controlled packaging with full tracking and are covered by our 再発送保証ポリシー.
Other Peptides for Anabolic, Growth-Axis, and Muscle Studies
- IGF-1 LR3 — Long-arginine recombinant IGF-1 analog — direct IGF-1R agonist for Akt/mTOR studies
- CJC-1295 with DAC — Long-acting GHRH analog — growth hormone axis support
- Sermorelin — Shorter-acting GHRH(1-29) analog — natural GH-pulse support
- Ipamorelin — 選択的グレリン作動薬 — コルチゾール/プロラクチンを伴わないクリーンなGHパルス
- TB-500(サイモシンベータ-4) — Systemic healing fragment — muscle and cardiac recovery
参考文献
📖 Explore anabolic and growth-axis peptides
すべてを閲覧 ペプチドカタログ, 、関連化合物として IGF-1 LR3 for direct IGF-receptor anabolic studies, CJC-1295 with DAC for long-acting GHRH use, and TB-500 for systemic muscle and tissue recovery.















レビュー
まだレビューはありません